

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D.C. 20231 on April 12, 2000

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney



PETITION AND FEE FOR EXTENSION
OF TIME UNDER 37 CFR 1.136(a)
Examining Group 1644
Patent Application
Docket No. SPO-103
Serial No. 09/142,524

RECEIVED
APR 20 2000
FIC 1500 MAIL ROOM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : M. DiBrino, Ph.D.
Art Unit : 1644
Applicant : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino
Serial No : 09/142,524
Filed : September 9, 1998
For : Peptide-based Immunotherapeutic Agent for Treating Allergic Diseases

Assistant Commissioner for Patents
Washington, D.C. 20231

PETITION AND FEE FOR EXTENSION OF TIME
UNDER 37 CFR 1.136(a)

Sir:

The applicants request that the period for response be extended three months through and including April 12, 2000. An Amendment Under 37 CFR 1.111 accompanies this Petition. Please charge the fee of \$870.00 to Deposit Account 19-0065.

Any additional fees as required by 37 CFR 1.16 or 1.17 should be charged to Deposit Account No. 19-0065. Two copies of this Petition are enclosed for deposit account authorization.

Respectfully submitted,

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D.
Patent Attorney

Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 NW 41st Street, Suite A-1
Gainesville, FL 32606-6669


FCE/la

Attachment: Amendment Under 37 CFR §1.111

04/19/2000 RTSEGAYE 00000056 190065 09142524

01 FCE/la 870.00 CH

AMENDMENT TRANSMITTAL LETTER			ATTORNEY'S DOCKET NO. SPO-103
SERIAL NO. 09/142,524	FILING DATE September 9, 1998	EXAMINER M. DiBrino, Ph.D.	GROUP ART UNIT 1644
INVENTION Peptide-based Immunotherapeutic Agent For Treating Allergic Diseases			



TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is an amendment in the above-identified application.

- ☐ Small entity status of this application under 37 CFR 1.27 has been established by a verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- ☐ No additional fee is required.
- ☒ The fee has been calculated as shown below:

(1)	(2)	(3)	SMALL ENTITY	OTHER THAN A SMALL ENTITY
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO. PREVIOUSLY PAID FOR	RATE	RATE
			ADDIT FEE	ADDIT FEE
TOTAL	* 29	** 20	\$ 9	\$ 18
INDEP.	* 2	***03	\$ 39	\$ 78
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			\$ 130	\$ 260
			Total addit. fee	Total addit. fee
			\$	\$ 162

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the Highest No. Previously Paid For IN THIS SPACE is less than 20, enter "20."

*** If the Highest No. Previously Paid For IN THIS SPACE is less than 3, enter "3."

The Highest No. Previously Paid For (Total or Indep.) is the highest number found in the appropriate box in Col. 1.

- ☒ Please charge my Deposit Account No. 19-0065 in the amount of \$162.00. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-0065. A duplicate copy of this sheet is enclosed.

☒ Any additional filing fees required under 37 CFR 1.16.☒ Any patent application processing fees under 37 CFR 1.17.

April 12, 2000

(date)

(signature)